News

Metabolism Influences Fibrosis in SSc

Fibrosis and metabolism: the two were recently linked in a study presented at the 2014 American College of Rheumatology Meeting in November. “Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism,” presented by Dr. Feng Fang from Northwestern…

iBio Presents Latest Developments on IBIO-CFB03 for Systemic Sclerosis

iBio, Inc. has released the latest information on the development of IBIO-CFB03, a therapy designed to address significant unmet medical needs for the treatment of fibrotic diseases, including systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). The company, which creates plant-derived pharmaceutical products, presented the news to their shareholders and other attendees at…

FDA Grants Conditional Approval For Cytori’s Scleroderma Therapy Trial

Cytori Therapeutics, Inc., a company developing autologous ADRCs-based cell therapies for the treatment of several conditions, including scleroderma, has been granted conditional approval by the U.S. Food and Drug Administration (FDA), for an Investigational Device Exemption (IDE) for their investigational scleroderma therapy. The pivotal trial, dubbed “STAR,” aims to evaluate the potential of Cytori Cell Therapy,…

First Patient Enrolled in Drug Study for Scleroderma-Related Raynaud’s

Biopharmaceutical company Apricus Biosciences, Inc. announced it has successfully enrolled the first patient for a Phase 2a clinical trial for RayVa™, the company’s frontline candidate for scleroderma-related Raynaud’s phenomenon. Scleroderma, classified among autoimmune rheumatic diseases, causes hardening or spontaneous scarring of the skin, internal organs,…

New Scleroderma Criteria Improves Upon Disease Classification

The American College of Rheumatology (ACR), together with the European League Against Rheumatism (EULAR) published new criteria for classification of systemic sclerosis. The new guidelines were introduced to allow earlier diagnosis and facilitate more targeted therapeutic treatments. The criteria were published in the journal of Arthritis & Rheumatism in…

Localized Scleroderma Characterized by T-Cell Cytokines and Chemokines

New Scleroderma-related findings have linked two variations of the disease, which in turn could lead to effective, new biomarkers and targeted treatments for patients. Two clinically different diseases, localized scleroderma (LS) and systemic sclerosis (SSc), can be characterized by similar T-cell produced cytokines and chemokines in pediatric patients,…

Autotaxin Protein Can Be Targeted in SSc Therapy

A group from Massachusetts General Hospital is placing possible blame for systemic sclerosis (SSc) pathogenesis on autotaxin (ATX), an enzyme involved in the production of the lipid signaling molecule lysophophatidic acid (LPA). Dr. Falvia V. Castelino, a researcher in the Rheumatology Department, presented the group’s work, “…

Probiotics Investigated in SSc Patients with GI Symptoms

Federal University of São Paulo recently initiated a phase 3 clinical trial evaluating the use of probiotics in patients with systemic sclerosis (SSc) to determine the efficacy and safety of treating gastrointestinal symptoms of SSc. As an autoimmune disease, SSc may benefit from probiotics due to their ability to…